EGFR and head and neck squamous cell carcinoma: Approved for HNSCC, the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab (E) is used for system treatment of recurrent or metastatic (R/M) HNSCC alone or in combination with PF [EXTREME (27–29)] or TP [TPExtreme (30) within the TREMPLIN-II study (31)], IC with TPF followed by radiochemotherapy with three more cycles P or bioradiotherapy with E weekly showed no significant differences in LOP and OS.